Member Organizations

Critical Innovations LLC

About Critical Innovations LLC

Winner of the MTEC 2020 Prototype of the Year Award, Critical Innovations LLC is an ISO 13485:2016 certified, 21 CFR§820 QSR (cGMP) and DCAA compliant, medical research and development company focused on creating cutting-edge solutions to health threats that span the pre-hospital, hospital, and military environments.  The FDA-registered small business employs an iterative development methodology focused on human factors engineering to rapidly advance products.

Company focus areas include:

  • Combat Casualty Care
  • Critical Care
  • Emergency Medical Services
  • Emergency Medicine
  • Prolonged Field Care
  • Trauma Care
  • Traumatic Brain Injury
  • Wound Care

Critical Innovations is currently developing multiple medical devices toward regulatory clearance. The company focuses on task-shifting evidence-based interventions to earlier echelons of care and more general specialty levels, to simplify management and allow for rapid provision in emergency and combat environments. To date, the company has worked under more than 20 different Department of Defense awards from all three military branches charged with medical technology development (i.e. U.S. Army, Air Force, and Navy), including such agencies as the Air Force Medical Support Agency; Army Medical Research and Development Command; Defense Health Agency; and, Office of Naval Research. Contract types have included Small Business Innovation Research (SBIR), Joint Warfighter, and Other Transactional Authority. As a prime contractor, Critical Innovations currently has a 100% transition rate from Phase I to Phase II, as well as Phase II to Phase III, for all eligible SBIR programs.

Core company technologies:

  • BurRapid™ Intracranial Access Platform
  • Donaldson Decompression Needle™
  • Fast Onset Abdominal Management™ (F.O.A.M.™)
  • PleuraPath™ Thoracostomy System
  • Succor™ Combat Foam

Ross I. Donaldson, MD, MPH, CTropMed, FACEP – President & CEO
Timothy Fisher, M.B. Ch.B. – Vice President of Research
Jonathan Armstrong, PhD, CSci, CChem FRSC – Director of Quality Assurance & Regulatory Affairs
Oliver Buchanan, BSc (Hons) – Director of Development & Engineering
John Cambridge, PhD – Director of Special Projects
Perry Lew, MS, MBA – Director of Operations 

Contact Information:

Phil and Penny Knight Campus for Accelerating Scientific Impact at the University of Oregon

About the Phil and Penny Knight Campus for Accelerating Scientific Impact at the University of Oregon

The Phil and Penny Knight Campus for Accelerating Scientific Impact is an ambitious initiative to fast-track scientific discoveries into innovations that improve the quality of life for people in Oregon, the nation, and the world. The campus creates the intellectual infrastructure to establish Oregon as a center for both research and development, making Oregon a place where companies can start-up, grow, and stay.

Mission: Science advancing society

Vision: Dramatically shorten the timeline between discovery and societal impact through world-class research, training and entrepreneurship in a nimble scientific enterprise.


  • Redefine the modern research university by fostering world-changing research unfettered by traditional academic boundaries
  • Serve as the educational engine driving the new economy of Oregon
  • Transform student education through discovery-driven learning
  • Engage the public in the excitement and creativity of scientific research
  • Foster diverse perspectives and participation in scientific research
  • Improve the health and wellbeing of the citizens of Oregon, the nation, and the world

Robert Guldberg – Vice President and Robert and Leona DeArmond Executive Director
Jim Hutchison – Senior Associate Vice President and Lokey-Harrington Chair in the Department of Chemistry and Biochemistry
Moira Kiltie – Associate Vice President and Chief of Staff
Andrew Nelson – Associate Vice President of Entrepreneurship and Innovation, Randall C. Papé Chair in Entrepreneurship and Innovation, and Associate Professor of Management

Contact Information:
Twitter: @UOKnightCampus

Wake Forest Institute for Regenerative Medicine (WFIRM)

About the Wake Forest Institute for Regenerative Medicine (WFIRM)

The Wake Forest Institute for Regenerative Medicine is recognized as an international leader in translating scientific discovery into clinical therapies, with many world firsts, including the development and implantation of the first engineered organ in a patient. Over 400 people at the institute, the largest in the world, work on more than 40 different tissues and organs. A number of the basic principles of tissue engineering and regenerative medicine were first developed at the institute. WFIRM researchers have successfully engineered replacement tissues and organs in all four categories – flat structures, tubular tissues, hollow organs and solid organs – and 15 different applications of cell/tissue therapy technologies, such as skin, urethras, cartilage, bladders, muscle, kidney, and vaginal organs, have been successfully used in human patients. The institute, which is part of Wake Forest School of Medicine, is located in the Innovation Quarter in downtown Winston-Salem, NC, and is driven by the urgent needs of patients. The institute is making a global difference in regenerative medicine through collaborations with over 400 entities and institutions worldwide, through its government, academic and industry partnerships, its start-up entities, and through major initiatives in breakthrough technologies, such as tissue engineering, cell therapies, diagnostics, drug discovery, biomanufacturing, nanotechnology, gene editing and 3D printing.

Anthony Atala, MD – G. Link Professor and Director
James Yoo, MD, PhD – Chief Operations Program Officer
Shay Soker, PhD – Chief Scientific Program Officer

Contact Information:
Twitter: @WFIRMnews
Facebook: @WFIRMnews